Last reviewed · How we verify
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously and Intranasally in Patients With Parkinson's Disease
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Parkinson's Disease and clinical outcomes.
Details
| Lead sponsor | Ageless Regenerative Institute |
|---|---|
| Phase | NA |
| Status | WITHDRAWN |
| Start date | 2014-05 |
| Completion | 2017-12 |
Conditions
- Parkinson's Disease
Interventions
- Harvesting and Implantation of Adipose-Derived Stem Cells
Primary outcomes
- UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE)-Behavior — 3 months
Improvement in Mentation, Behavior and mood in on and off position - Number of participants with adverse events — 1 week
- UPDRS- Improvement in Activities of Daily Living — 3 months
- UPDRS- Improvement in motor Examination — 3 months
Values compared to baseline - UPDRS- MODIFIED HOEHN AND YAHR STAGING — 3 months
Compared to baseline - UPDRS- SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE — 3 months
Countries
United States